MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijcard.2020.03.038

Медицинская библиотека · International journal of cardiology · 2020

Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement.

Biancari Fausto, Dahlbacka Sebastian, Juvonen Tatu, Virtanen Marko P O, Maaranen Pasi, Jaakkola Jussi, Laakso Teemu, Niemelä Matti, Tauriainen Tuomas, Vento Antti, Husso Annastiina, Savontaus Mikko, Laine Mika, Mäkikallio Timo, Raivio Peter, Eskola Markku, Rosato Stefano, Anttila Vesa, Airaksinen Juhani, Valtola Antti

СтатьяПеревод пока не подготовлен

Аннотация

AIM: The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer.

METHODS

This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017.

RESULTS

In this cohort, 417 patients (19.6%) had history of cancer and 113 (5.3%) had an active malignancy at the time of TAVR. Patients with any malignancy had similar late mortality than patients without any malignancy (at 7 years, 65.1% vs. 59.3%, adjusted HR 1.105, 95%CI 0.892-1.369). At 7 years, cancer-related mortality was 22.5% among patients with preoperative cancer, and 11.0% in those without preoperative cancer (p < 0.0001). Among cancer patients, 18 died of the same disease (at 7 years, mortality 12.5%). Active malignancy was not associated with increased risk of all-cause mortality (adjusted HR 1.100, 95%CI 0.757-1.599). However, patients with blood malignancies had a significantly increased risk of mortality (at 4-year, 53.5% vs. 35.4%, adjusted HR 2.029, 95%CI 1.328-3.098).

CONCLUSIONS

This analysis showed that, when properly selected by the heart team and oncologists, most cancer patients undergoing TAVR can achieve a good survival and eventually die of other diseases. Blood malignancies seem to carry a poor prognosis in these patients.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03385915; https://clinicaltrials.gov/ct2/show/NCT03385915.

Для цитирования: Biancari Fausto, Dahlbacka Sebastian, Juvonen Tatu, Virtanen Marko P O, Maaranen Pasi, Jaakkola Jussi, Laakso Teemu, Niemelä Matti, Tauriainen Tuomas, Vento Antti, Husso Annastiina, Savontaus Mikko, Laine Mika, Mäkikallio Timo, Raivio Peter, Eskola Markku, Rosato Stefano, Anttila Vesa, Airaksinen Juhani, Valtola Antti. Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement.. International journal of cardiology. 2020. DOI: 10.1016/j.ijcard.2020.03.038.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.